Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Orazi

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
American Journal of Ophthalmology Case Reports|August 22, 2019
Familial exudative retinopathy <i>TSPAN12</i> positive presenting as bilateral retinal stalks: late structural and functional findingsGiulia M Amorelli, Marco H Ji, Lorenzo Orazi, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|October 26, 2020
Familial Exudative Vitreoretinopathy With Neurodevelopmental Delay and Hypoplasia of the Corpus CallosumGiulia M Amorelli, Costanza Barresi, Marco H Ji, et al.
Eye (London, England)|January 20, 2021
Early angiographic signs of retinopathy of prematurity requiring treatmentDomenico Lepore, Marco H Ji, Gui-Shuang Ying, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|March 27, 2020
Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROPDomenico Lepore, Marco H Ji, Graham E Quinn, et al.
International Journal of Legal Medicine|January 24, 2022
The role of retinal imaging in the management of abusive head trauma casesAntonio Oliva, Simone Grassi, Francesca Cazzato, et al.
Ophthalmology|July 9, 2014
Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology|September 5, 2017
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic FindingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology. Retina|September 3, 2019
Retinopathy of Prematurity Reactivated 28 Months after Injection of RanibizumabMarco H Ji, Darius M Moshfeghi, Natalia F Callaway, et al.
European Journal of Ophthalmology|July 30, 2020
Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effectMarco H Ji, Darius M Moshfeghi, Ryan A Shields, et al.
Journal of Inherited Metabolic Disease|August 17, 2024
Improved biochemical and neurodevelopmental profiles with high-dose hydroxocobalamin therapy in cobalamin C defectGiorgia Olivieri, Benedetta Greco, Sara Cairoli, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
American Journal of Ophthalmology Case Reports|August 22, 2019
Familial exudative retinopathy <i>TSPAN12</i> positive presenting as bilateral retinal stalks: late structural and functional findingsGiulia M Amorelli, Marco H Ji, Lorenzo Orazi, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|October 26, 2020
Familial Exudative Vitreoretinopathy With Neurodevelopmental Delay and Hypoplasia of the Corpus CallosumGiulia M Amorelli, Costanza Barresi, Marco H Ji, et al.
Eye (London, England)|January 20, 2021
Early angiographic signs of retinopathy of prematurity requiring treatmentDomenico Lepore, Marco H Ji, Gui-Shuang Ying, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|March 27, 2020
Functional and Morphologic Findings at Four Years After Intravitreal Bevacizumab or Laser for Type 1 ROPDomenico Lepore, Marco H Ji, Graham E Quinn, et al.
International Journal of Legal Medicine|January 24, 2022
The role of retinal imaging in the management of abusive head trauma casesAntonio Oliva, Simone Grassi, Francesca Cazzato, et al.
Ophthalmology|July 9, 2014
Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology|September 5, 2017
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic FindingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology. Retina|September 3, 2019
Retinopathy of Prematurity Reactivated 28 Months after Injection of RanibizumabMarco H Ji, Darius M Moshfeghi, Natalia F Callaway, et al.
European Journal of Ophthalmology|July 30, 2020
Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effectMarco H Ji, Darius M Moshfeghi, Ryan A Shields, et al.
Journal of Inherited Metabolic Disease|August 17, 2024
Improved biochemical and neurodevelopmental profiles with high-dose hydroxocobalamin therapy in cobalamin C defectGiorgia Olivieri, Benedetta Greco, Sara Cairoli, et al.
Pageof 3